Abstract:Objective: To screen and perform preliminary clinical validation of biomarkers of activity based on positron emission tomography/computed tomography (PET-CT) and transcriptomics in sputum-negative pulmonary tuberculosis lesion tissue. Methods: Nine patients with sputum-negative pulmonary tuberculosis treated surgically at the Shanghai Public Health Clinical Center for Thoracic Surgery from January 1, 2017 to December 31, 2019 were retrospectively collected as the discovery group, including four males and five females, aged 20-57 years (mean 36 years). All of the patients underwent PET-CT scanning before surgery, and the resected specimens were postoperatively classified according to preoperative PET-CT. The resected specimens were divided into areas with increased fluorodeoxyglucose (FDG) metabolism (SUVmax>3) and areas with normal FDG metabolism (SUVmax ≤ 3) according to the preoperative PET-CT performance. After sample processing, total RNA was extracted from the tissues of different regions, and then whole gene transcriptome sequencing was performed. Bioinformatics analysis of the two sets of data was performed to discover the expression profiles of the differences in whole gene transcriptome data between the two regions and to screen for candidate biomarkers. Eighty patients with sputum-negative pulmonary tuberculosis admitted to Shanghai Public Health Clinical Center from January 1, 2019 to January 1, 2021 were retrospectively collected as the validation group, including 37 males and 43 females, aged 20-62 years, with an average age of 39 years. The validation group was divided into a group with increased SUV (n=40) and a group without lesions on CT imaging (n=40). Enzyme-linked immunosorbent assay (ELISA) was used to determine the protein levels of candidate biomarkers in the peripheral plasma of patients. The effect of biomarkers was assessed using subject operating characteristic (ROC) curves. Student's t-test was used to determine whether the difference in protein levels between the two groups was statistically significant. Results: Bioinformatics analysis revealed that the expression levels of C1QB, CCL19, CCL5 and HLA-DMB correlated with the metabolic activity of sputum-negative tuberculosis lesion tissue. Further screening and validation by the validation group confirmed that the difference in C1QB protein levels in the peripheral plasma of patients was statistically significant between the group with increased SUV and the group without lesions on CT imaging [(3.55±0.34) mg/L vs. (2.75±0.21) mg/L, t=4.12, P<0.001]. And the ROC curve showed that the area under the curve for C1QB protein levels was 0.731, which had potential clinical value. Conclusion: The C1QB protein level can be used to assess the activity of lesions in patients with sputum-negative tuberculosis and is a potential biomarker.

Identification of Potential Urine Proteins and Microrna Biomarkers for the Diagnosis of Pulmonary Tuberculosis Patients.

Urinary proteomic analysis to identify a potential protein biomarker panel for the diagnosis of tuberculosis

Discovery and Identification of Serum Potential Biomarkers for Pulmonary Tuberculosis Using Itraq-Coupled Two-Dimensional Lc-Ms/Ms

Screening And Identification Of Six Serum Micrornas As Novel Potential Combination Biomarkers For Pulmonary Tuberculosis Diagnosis

Proteomic Profiling for Plasma Biomarkers of Tuberculosis Progression

Urinary metabolomic analysis to identify potential markers for the diagnosis of tuberculosis and latent tuberculosis

MiRNA-155 and Mirna-132 As Potential Diagnostic Biomarkers for Pulmonary Tuberculosis: A Preliminary Study.

Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS.

Characterization of cytokine profile to distinguish latent tuberculosis from active tuberculosis and healthy controls.

Identification of putative biomarkers for the serodiagnosis of drug-resistant Mycobacterium tuberculosis

Proteomic Analysis of Sputum in Patients with Active Pulmonary Tuberculosis

Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection

Early Diagnosis of Pulmonary Tuberculosis Using Serum Biomarkers

Identification of New Diagnostic Biomarkers for Mycobacterium Tuberculosis and the Potential Application in the Serodiagnosis of Human Tuberculosis

Discovery of Potential Plasma Biomarkers for Tuberculosis in HIV-Infected Patients by Data-Independent Acquisition-Based Quantitative Proteomics.

Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis

A proteomics approach to the identification of plasma biomarkers for latent tuberculosis infection.

[Screening and Preliminary Validation of Biomarkers in Sputum-Negative Pulmonary Tuberculosis Based on Positron Emission Tomography/computed Tomography and Transcriptomics].

New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Diagnostic serum proteomic analysis in patients with active tuberculosis

Single molecule measurements of microRNAs in the serum of patients with pulmonary tuberculosis